查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1662732

2030 年神经病变疼痛市场预测：按药物类别、适应症、患者类型、给药途径、分销管道和地区进行的全球分析

Neuropathic Pain Market Forecasts to 2030 - Global Analysis By Drug Class (Antidepressants, Anticonvulsant, Opioids, Capsaicin, Steroids and Other Drug Classes), Indication, Patient Type, Route of Administration, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球神经病变疼痛市场预计在 2024 年达到 82.4 亿美元，预计到 2030 年将达到 143.5 亿美元，预测期内的复合年增长率为 9.7%。

神经病变疼痛是一种因神经系统损伤或功能障碍而导致的复杂慢性疼痛疾病。糖尿病、带状疱疹、多发性硬化症和神经损伤是一些经常引起神经性疼痛的疾病。这种疼痛可能伴随对触觉和温度变化的敏感性，并可能以灼热、刺痛、麻刺或麻木感为特征。它可能很难治疗，需要多管齐下的策略，包括药物治疗、物理治疗、神经阻断和咨询。此外，由于疾病严重影响患者的生活质量，因此早期诊断和有效治疗对于改善患者预后至关重要。

根据美国美国卫生研究院在 PubMed Central 上发表的叙述性评论，神经病变疼痛影响约 7-10% 的一般人群。

神经病变疾病呈上升趋势

神经病变疼痛通常与糖尿病、带状疱疹后遗症神经痛、多发性硬化症和创伤性神经损伤等潜在疾病有关。例如，研究表明，大约 50% 的糖尿病患者最终会发展为糖尿病神经病变，这是导致全球糖尿病发病率上升的一个主要因素。此外，老化社会容易出现神经退化，增加神经病变疾病等与老龄化相关的疾病的盛行率。由于这些病症的盛行率不断上升，对有效的疼痛管理治疗的需求也随之增加。随着患有神经病变疼痛的人数增加，治疗方法和诊断设备的市场也预计将成长。

缺乏有效治疗方法

人们仍然迫切需要改进的、长期的、真正有效的神经病变疼痛治疗​​治疗方法。目前可用的许多治疗方法只能提供部分缓解，有些还会引起不良的副作用，例如疲劳、头晕和消化器官系统问题。例如，虽然阿片类药物可用于治疗急性疼痛，但由于成瘾和依赖的风险较高，其在治疗慢性疼痛方面的应用受到限制。此外，有些患者对常见的合併用药没有反应，这使得寻找正确的治疗方法既费时又令人沮丧。

个性化医疗的演变

个人化医疗趋势是神经性疼痛市场最令人兴奋的前景之一。随着研究的进展，我们对导致神经性疼痛的遗传、分子和环境因素有了更好的了解。根据患者的基因特征、疼痛途径和药物治疗反应进行个人化治疗可以实现更有效、更有针对性的疼痛缓解，且副作用更少。此外，该公司已经开始研究基因标记来预测患者对某些神经病变疼痛药物的反应。该策略有可能显着提高治疗成功率，减少试验，并为患者提供更个人化的疼痛管理选择。

学名药的激烈竞争

神经病变疼痛市场正受到学名药出现的严重威胁。目前，许多用于治疗神经病变疼痛的药物都有学名药，包括Duloxetine、Pregabalin和Gabapentin。学名药通常比品牌药便宜得多，大大减少了开发专有配方的公司的获利机会。由于学名药的激烈竞争，製药公司被迫降价，这可能会降低利润率。此外，随着神经病变止痛药专利到期到期，学名药将进入市场，价格竞争可能会更加激烈。

COVID-19 的影响

COVID-19 疫情对神经性疼痛市场产生了显着影响，既有正面的，也有负面的。由于医院和诊所将资源集中在治疗新冠肺炎患者上，全球卫生危机导致卫生系统中断，包括神经病变疼痛的诊断和治疗延迟。常规预约和选择性手术被推迟，导致患者错过了专门的疼痛管理治疗。疫情引发的经济景气衰退所带来的财务限制也使患者难以支付医疗费用，尤其是那些需要先进疗法和手术的患者。

糖尿病神经病变领域预计将在预测期内增长至最大的领域

预计预测期内糖尿病神经病变部分将占据最大的市场占有率。这种优点是由于全球糖尿病盛行率高，导致大量人罹患糖尿病神经病变。例如，国际糖尿病联盟（IDF）预测，到2022年，20岁至79岁的成年人将有6.43亿人罹患糖尿病，到2030年，这一数字将上升到7.83亿人。此外，大量的糖尿病患者加强了该领域的市场占有率，增加了对糖尿病神经病变有效治疗的需求。

预计预测期内成人市场将达到最高的复合年增长率。

预计在预测期内成人市场将呈现最高的成长率。这种增长的主要原因是成人带状疱疹后遗症神经痛和糖尿病神经病变等疾病的发生率不断增加。例如，国际糖尿病联盟（IDF）预测，到2022年，20岁至79岁的成年人将有6.43亿人罹患糖尿病，到2030年，这一数字将上升到7.83亿人。此外，大量的糖尿病患者对糖尿病神经病变的有效治疗的需求也随之增加，从而加强了该领域的市场占有率。

比最大的地区

预计预测期内北美地区将占据最大的市场占有率。造成这种优越性的主要原因是成人常见的神经病变疾病的发生率较高，例如糖尿病性神经病变、带状疱疹后遗症神经痛、化疗引起的周边神经病变。医疗保健基础设施的完善以及治疗意识和治疗选择机会的增加也显着影响着该领域的市场发展。此外，由于糖尿病等慢性疾病患者数量的增加以及新的疼痛管理治疗方法的持续研发，北美在市场中占据领先地位。

复合年增长率最高的地区

预计预测期内亚太地区将呈现最高的复合年增长率。糖尿病神经病变和其他神经病变疾病的盛行率不断上升，以及该地区医疗保健基础设施和医疗服务机会的改善，是这种快速增长的主要原因。人们对神经病变疼痛及其可用治疗方法的认识不断提高，以及中国和印度等国家经济状况和医疗支出的改善，也推动了对有效疼痛管理治疗的需求。此外，这些因素正在推动未来几年亚太地区强劲的成长预测。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 对其他市场参与企业（最多 3 家公司）进行全面分析
    • 主要企业的 SWOT 分析（最多 3 家公司）
  • 地理细分
    • 根据客户兴趣对主要国家进行市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争性基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第 2 章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二手研究资料资讯来源
    • 先决条件

第三章 市场走势分析

  • 介绍
  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 新兴市场
  • COVID-19 的影响

第 4 章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球神经病变疼痛市场（依药物类别）

  • 介绍
  • 抗忧郁症
    • 三环抗忧郁药物
    • 血清素-正肾上腺素再回收抑制剂(SNRI)
  • 抗惊厥药
  • 阿片类药物
  • 辣椒素
  • 类固醇
  • 其他的

6. 全球神经病变疼痛市场（依适应症划分）

  • 介绍
  • 糖尿病神经病变
  • 脊椎狭窄
  • 带状疱疹后遗症神经痛
  • 化疗引起的周边神经病变
  • 其他的

7. 全球神经病变疼痛市场（依患者型态）

  • 介绍
  • 成人
  • 老年人
  • 孩子们

8. 全球神经病变疼痛市场依给药途径划分

  • 介绍
  • 口服
  • 经皮
  • 静脉
  • 局部的

9. 全球神经病变疼痛市场（依分销管道）

  • 介绍
  • 医院药房
  • 零售药局
  • 网路药局

10. 全球神经病变疼痛市场（按地区）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Abbott Laboratories
  • Pfizer, Inc
  • Sanofi SA
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Teva Pharmaceutical Industries Ltd.
  • Baxter Healthcare Corporation
  • Collegium Pharmaceutical, Inc.
  • Mallinckrodt Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd
  • Glenmark Pharmaceuticals Limited
  • Bristol-Myers Squibb Company
  • Grunenthal GmbH
Product Code: SMRC28593

According to Stratistics MRC, the Global Neuropathic Pain Market is accounted for $8.24 billion in 2024 and is expected to reach $14.35 billion by 2030 growing at a CAGR of 9.7% during the forecast period. Neuropathic pain is a complex, chronic pain condition that arises due to damage or dysfunction in the nervous system. Diabetes, shingles, multiple sclerosis, and nerve injuries are among the conditions that frequently cause it. This kind of pain can be accompanied by hypersensitivity to touch or temperature changes and is typified by feelings of burning, stabbing, tingling, or numbness. It can be difficult to treat, necessitating a multimodal strategy that may involve drugs, physical therapy, nerve blocks, and counselling. Moreover, a person's quality of life is greatly impacted by the condition, so improving patient outcomes requires early diagnosis and efficient treatment.

According to a narrative review published in the National Institutes of Health's PubMed Central, neuropathic pain does indeed affect approximately 7-10% of the general population.

Market Dynamics:

Driver:

Growing number of neuropathic disorders

Neuropathic pain is often associated with underlying conditions such as diabetes, post-herpetic neuralgia, multiple sclerosis, and traumatic nerve injuries. For instance, studies indicate that about 50% of individuals with diabetes will eventually develop diabetic neuropathy, making the global increase in diabetes a major contributing factor. Furthermore, nerve degeneration is more likely to occur in an aging population, which increases the prevalence of age-related disorders like neuropathy. The need for efficient pain management treatments is fueled by the increasing prevalence of these illnesses. The market for therapies and diagnostic equipment is anticipated to expand in tandem with the rise in the number of people experiencing neuropathic pain.

Restraint:

Absence of effective treatment choices

Even with improvements in neuropathic pain management, there is still a big need for long-term, really effective therapies. Many of the treatments available today only offer partial relief, and some have unfavorable side effects like fatigue, lightheadedness, or digestive problems. For instance, opioid drugs are useful for treating acute pain, but their use in treating chronic pain is restricted due to their high potential for addiction and dependency. Additionally, some patients might not respond to commonly prescribed medications, which can cause frustration and delay in locating an appropriate course of treatment.

Opportunity:

Evolution of personalized medicine

The trend toward personalized medicine is one of the most exciting prospects in the market for neuropathic pain. The genetic, molecular, and environmental factors that contribute to neuropathic pain are becoming better understood as research progresses. More effective and targeted pain relief with fewer side effects may be possible with personalized treatments based on a patient's genetic profile, pain pathways, and reaction to medication. Moreover, businesses are already looking into genetic markers to forecast a patient's reaction to particular neuropathic painkillers. This strategy could significantly increase treatment success rates, cut down on trial and error, and provide patients with more individualized pain management options, making it a very profitable area for innovation.

Threat:

Vigorous competition from generic medicines

The market for neuropathic pain is seriously threatened by the availability of generic medications. There are now generic versions of many drugs used to treat neuropathic pain, including duloxetine, pregabalin, and gabapentin. Since generic medications are usually far less expensive than their branded equivalents, businesses that have created unique formulations have a much smaller chance of making money. Pharmaceutical companies are under pressure to cut prices due to the fierce competition from generics, which can reduce profit margins. Additionally, this price competition will also get more intense as generic versions of neuropathic painkillers continue to hit the market as more patents for these drugs expire.

Covid-19 Impact:

The market for neuropathic pain was significantly impacted by the COVID-19 pandemic, both positively and negatively. As hospitals and clinics concentrated their resources on treating COVID-19 cases, the global healthcare crisis caused disruptions in healthcare systems, including delays in the diagnosis and treatment of neuropathic pain. Patients had less access to specialized pain management therapies as a result of routine appointments and elective procedures being delayed. Financial limitations brought on by the pandemic's economic downturn also made it harder for patients to pay for treatments, particularly those that required sophisticated therapies or procedures.

The Diabetic Neuropathy segment is expected to be the largest during the forecast period

The Diabetic Neuropathy segment is expected to account for the largest market share during the forecast period. This dominance is explained by the high global prevalence of diabetes, which causes diabetic neuropathy in a considerable number of people. The International Diabetes Federation (IDF), for example, projected that by 2022, 643 million adults between the ages of 20 and 79 would have diabetes by 2030, and by 2045, that number would have increased to 783 million. Moreover, the market share of this segment is strengthened by the large number of diabetics, which raises the need for efficient treatments for diabetic neuropathy.

The Adult segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Adult segment is predicted to witness the highest growth rate. The main cause of this growth is the rising incidence of diseases like postherpetic neuralgia and diabetic neuropathy in adults. The International Diabetes Federation (IDF), for example, projected that by 2022, 643 million adults between the ages of 20 and 79 would have diabetes by 2030, and by 2045, that number would have increased to 783 million. Additionally, the market share of this segment is strengthened by the large number of diabetics, which raises the need for efficient treatments for diabetic neuropathy.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share. The main cause of this dominance is the high frequency of neuropathic conditions that are more common in adults, such as diabetic neuropathy, post herpetic neuralgia, and chemotherapy-induced peripheral neuropathy. The development of the market in this area is also greatly influenced by the existence of sophisticated healthcare infrastructure, as well as by greater awareness of and access to treatment options. Furthermore, North America leads the market due to the growing number of people with chronic illnesses like diabetes and the continuous research and development of new pain management treatments.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR. The increasing prevalence of diabetic neuropathy and other neuropathic conditions, as well as the region's growing healthcare infrastructure and improved access to healthcare, are the main causes of this rapid growth. The need for efficient pain management treatments is also being fueled by rising awareness of neuropathic pain and its available treatments, as well as bettering economic conditions and healthcare spending in nations like China and India. Moreover, the strong growth prediction for the APAC region in the upcoming years is influenced by these factors.

Key players in the market

Some of the key players in Neuropathic Pain market include Abbott Laboratories, Pfizer, Inc, Sanofi S.A., Johnson & Johnson Services, Inc., Novartis AG, Eli Lilly and Company, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Ltd., Baxter Healthcare Corporation, Collegium Pharmaceutical, Inc., Mallinckrodt Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Limited, Bristol-Myers Squibb Company and Grunenthal GmbH.

Key Developments:

In December 2024, Teva Pharmaceutical Industries Ltd. announced that it has entered into an agreement with JKI, established by the fund managed and operated by J-Will, whereby all shares of Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd. will be transferred to JKI.

In September 2024, Abbott India Limited has signed a non-exclusive patent license agreement with Takeda Pharmaceuticals Company Limited to market and distribute "Vonoprazan" in India under the brand name "Vonefi". Vonoprazan addresses severe acid related disorders like reflux esophagitis through a once daily dose.

In August 2024, Johnson & Johnson1 announced that it has entered into a definitive agreement to acquire V-Wave Ltd., a privately-held company focused on developing innovative treatment options for patients with heart failure. Under the terms of the agreement, Johnson & Johnson will acquire V-Wave for an upfront payment of $600 million, subject to customary adjustments, with the potential for additional regulatory and commercial milestone payments up to approximately $1.1 billion.

Drug Classes Covered:

  • Antidepressants
  • Anticonvulsant
  • Opioids
  • Capsaicin
  • Steroids
  • Other Drug Classes

Indications Covered:

  • Diabetic Neuropathy
  • Spinal Stenosis
  • Post-Herpetic Neuralgia
  • Chemotherapy-Induced Peripheral Neuropathy
  • Other Indications

Patient Types Covered:

  • Adult
  • Geriatric
  • Pediatric

Route of Administrations Covered:

  • Oral
  • Transdermal
  • Intravenous
  • Topical

Distribution Channels Covered:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neuropathic Pain Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Antidepressants
    • 5.2.1 Tricyclic Antidepressants
    • 5.2.2 Serotonin-Noradrenaline Reuptake Inhibitors (SNRI)
  • 5.3 Anticonvulsant
  • 5.4 Opioids
  • 5.5 Capsaicin
  • 5.6 Steroids
  • 5.7 Other Drug Classes

6 Global Neuropathic Pain Market, By Indication

  • 6.1 Introduction
  • 6.2 Diabetic Neuropathy
  • 6.3 Spinal Stenosis
  • 6.4 Post-Herpetic Neuralgia
  • 6.5 Chemotherapy-Induced Peripheral Neuropathy
  • 6.6 Other Indications

7 Global Neuropathic Pain Market, By Patient Type

  • 7.1 Introduction
  • 7.2 Adult
  • 7.3 Geriatric
  • 7.4 Pediatric

8 Global Neuropathic Pain Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Oral
  • 8.3 Transdermal
  • 8.4 Intravenous
  • 8.5 Topical

9 Global Neuropathic Pain Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacy
  • 9.3 Retail Pharmacy
  • 9.4 Online Pharmacy

10 Global Neuropathic Pain Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott Laboratories
  • 12.2 Pfizer, Inc
  • 12.3 Sanofi S.A.
  • 12.4 Johnson & Johnson Services, Inc.
  • 12.5 Novartis AG
  • 12.6 Eli Lilly and Company
  • 12.7 GlaxoSmithKline PLC
  • 12.8 Teva Pharmaceutical Industries Ltd.
  • 12.9 Baxter Healthcare Corporation
  • 12.10 Collegium Pharmaceutical, Inc.
  • 12.11 Mallinckrodt Pharmaceuticals
  • 12.12 Sun Pharmaceutical Industries Ltd
  • 12.13 Glenmark Pharmaceuticals Limited
  • 12.14 Bristol-Myers Squibb Company
  • 12.15 Grunenthal GmbH

List of Tables

  • Table 1 Global Neuropathic Pain Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Neuropathic Pain Market Outlook, By Drug Class (2022-2030) ($MN)
  • Table 3 Global Neuropathic Pain Market Outlook, By Antidepressants (2022-2030) ($MN)
  • Table 4 Global Neuropathic Pain Market Outlook, By Tricyclic Antidepressants (2022-2030) ($MN)
  • Table 5 Global Neuropathic Pain Market Outlook, By Serotonin-Noradrenaline Reuptake Inhibitors (SNRI) (2022-2030) ($MN)
  • Table 6 Global Neuropathic Pain Market Outlook, By Anticonvulsant (2022-2030) ($MN)
  • Table 7 Global Neuropathic Pain Market Outlook, By Opioids (2022-2030) ($MN)
  • Table 8 Global Neuropathic Pain Market Outlook, By Capsaicin (2022-2030) ($MN)
  • Table 9 Global Neuropathic Pain Market Outlook, By Steroids (2022-2030) ($MN)
  • Table 10 Global Neuropathic Pain Market Outlook, By Other Drug Classes (2022-2030) ($MN)
  • Table 11 Global Neuropathic Pain Market Outlook, By Indication (2022-2030) ($MN)
  • Table 12 Global Neuropathic Pain Market Outlook, By Diabetic Neuropathy (2022-2030) ($MN)
  • Table 13 Global Neuropathic Pain Market Outlook, By Spinal Stenosis (2022-2030) ($MN)
  • Table 14 Global Neuropathic Pain Market Outlook, By Post-Herpetic Neuralgia (2022-2030) ($MN)
  • Table 15 Global Neuropathic Pain Market Outlook, By Chemotherapy-Induced Peripheral Neuropathy (2022-2030) ($MN)
  • Table 16 Global Neuropathic Pain Market Outlook, By Other Indications (2022-2030) ($MN)
  • Table 17 Global Neuropathic Pain Market Outlook, By Patient Type (2022-2030) ($MN)
  • Table 18 Global Neuropathic Pain Market Outlook, By Adult (2022-2030) ($MN)
  • Table 19 Global Neuropathic Pain Market Outlook, By Geriatric (2022-2030) ($MN)
  • Table 20 Global Neuropathic Pain Market Outlook, By Pediatric (2022-2030) ($MN)
  • Table 21 Global Neuropathic Pain Market Outlook, By Route of Administration (2022-2030) ($MN)
  • Table 22 Global Neuropathic Pain Market Outlook, By Oral (2022-2030) ($MN)
  • Table 23 Global Neuropathic Pain Market Outlook, By Transdermal (2022-2030) ($MN)
  • Table 24 Global Neuropathic Pain Market Outlook, By Intravenous (2022-2030) ($MN)
  • Table 25 Global Neuropathic Pain Market Outlook, By Topical (2022-2030) ($MN)
  • Table 26 Global Neuropathic Pain Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 27 Global Neuropathic Pain Market Outlook, By Hospital Pharmacy (2022-2030) ($MN)
  • Table 28 Global Neuropathic Pain Market Outlook, By Retail Pharmacy (2022-2030) ($MN)
  • Table 29 Global Neuropathic Pain Market Outlook, By Online Pharmacy (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.